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Abstract
Background: Research efforts for the management of cancer, in particular for lung cancer, are directed to identify
new strategies for its early detection. MicroRNAs (miRNAs) are a new promising class of circulating biomarkers for
cancer detection, but lack of consensus on data normalization methods has affected the diagnostic potential of
circulating miRNAs. There is a growing interest in techniques that allow an absolute quantification of miRNAs which
could be useful for early diagnosis. Recently, digital PCR, mainly based on droplets generation, emerged as an
affordable technology for precise and absolute quantification of nucleic acids.
Results: In this work, we described a new interesting approach for profiling circulating miRNAs in plasma samples
using a chip-based platform, the QuantStudio 3D digital PCR. The proposed method was validated using synthethic
oligonucleotide at serial dilutions in plasma samples of lung cancer patients and in lung tissues and cell lines.
Conclusion: Given its reproducibility and reliability, our approach could be potentially applied for the identification
and quantification of miRNAs in other biological samples such as circulating exosomes or protein complexes. As
chip-digital PCR becomes more established, it would be a robust tool for quantitative assessment of miRNA copy
number for diagnosis of lung cancer and other diseases.
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Background
MicroRNAs (miRNAs) are small non-coding RNAs,
19–24 nt-long, tissue specific, that regulate gene expres-
sion by post-trascriptional regulation [1, 2]. They play a
critical role in development and differentiation processes
of tissues and organs and are aberrantly expressed in dif-
ferent kinds of cancer [3, 4]. Over the last few years sev-
eral studies have shown that miRNAs can be detected
within body fluids such as plasma [5], serum [6], sputum
[7], saliva [8], and urine [9]. Although the mechanism of
secretion and incorporation of miRNAs has not been fully
clarified, circulating miRNAs may play a pivotal and gen-
eral role as signaling molecules in physiological and
pathological events [10].
Notably, circulating miRNAs levels were found to cor-
relate with cancer progression, therapeutic response, and
patient survival, suggesting that they could also be used
as non-invasive biomarkers [11, 12].
Lung cancer is the leading cause of cancer deaths in the
world due to its high incidence and mortality, with 5-year
survival estimates around 15 % for non-small-cell lung
cancer (NSCLC) [13]. Despite recent advances in the
management of lung cancer and the use of molecular
targeted agents in specific clinical settings, the cure rate
remains low due to drug-refractory recurrent disease [13].
We previously identified in tumor, normal lung tissue
and plasma samples miRNA signatures with diagnostic
and prognostic potential [14]. In a recent study we showed
that the combination of low dose computed tomography
(LDCT) screening and our plasma miRNA signatures
reduced LDCT false positives in a retrospective screening
series of more than 1000 individuals [15].
The high potential of the circulating miRNAs as mo-
lecular marker of disease is diminished by a lack of con-
sensus regarding an optimal method of normalization in
* Correspondence: orazio.fortunato@istitutotumori.mi.it
Gabriella Sozzi and Orazio Fortunato are co-last authors.
†Equal contributors
1Tumor Genomics Unit, Department of Experimental Oncology and
Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, via
Venezian 1, 20133 Milan, Italy
Full list of author information is available at the end of the article
© 2015 Conte et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Conte et al. BMC Genomics  (2015) 16:849 
DOI 10.1186/s12864-015-2097-9
plasma samples. The small-nucleolar RNAs (snoRNAs),
such as RNU6B and RNU48, cannot be used to this pur-
pose due to the absence in plasma [16]; other house-
keeping miRNAs candidate have been proposed in
different studies but a global consensus on their use is
still lacking [17, 18]. Alternatively, for assay with a rela-
tively large number of miRNAs, a normalization using
the mean or the median could be applied [19]. Our
group described an approach for circulating miRNAs
profiling in plasma samples based on the evaluation of
24 miRNAs reciprocal levels measured by quantitative
Real-Time PCR [20]. Recently, it was suggested an abso-
lute quantification of miRNAs using RT-PCR with a
standard curve generated with a synthetic oligonucleotide
but this approach could be useful only for individual
miRNA quantification but not for multiplex miRNA
evaluation. Furthermore, other groups proposed a
normalization method based on the addition of a spike-in
miRNAs. They recommended the use of C. elegans con-
trol miRNAs during the denaturation of samples to
normalize the variability that could affect the reaction
efficiency [21].
Digital PCR (dPCR) is an end-point PCR method that is
used for absolute quantification. The dPCR concept was
conceived in 1992 [22] and it was used to quantify KRAS
mutations in DNA from colorectal cancer patients [23].
Digital PCR has many potential applications, including the
detection and quantification of low-level pathogens [24],
rare genetic sequences [25], copy number variations
(CNVs) [26], gene expression in single cells [27] and quan-
tification of circulating miRNAs expression [28, 29].
Fig. 1 Workflow of a digital PCR experiment
Table 1 PCR run protocol
Step type Time Temperature (°C)
Hold 10 min 96
Cycle (40 cycles) 2 min 56
30 s 98
Hold 2 min 60
Hold ∞ 10
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In this work, we propose for the first time, a methodo-
logical workflow, shown in Fig. 1, for the absolute quan-
tification of miRNAs, in plasma or tissue/cells of lung
cancer patients using a chip-based platform, the Quant-
Studio 3D Digital PCR. For the description of the results
we adopted the guidelines for the publication of digital
PCR experiments described by Huggett et al. [30].
This innovative data analysis tool allowed us to cir-
cumvent the normalization issue and given the high re-
producibility of this procedure, we believe that it could





Plasma samples were collected from high-risk heavy
smoker volunteers aged from 50 to 75 years, including
current or former smokers with a minimum pack/year
index of 30 enrolled in a LDCT screening trial (BioMild)
performed at our Institution [31].









D1 500 598 83
D2 100 115 87
D3 20 25,24 78
D4 4 5,4 74
D5 0,8 1,08 74
D6 0,15 0,13 115
Fig. 2 Quantification of synthetic oligonucleotides by dPCR. Analysis of five-fold dilution series of cel-mir-39 using FAM and VIC probes. Representative plot
of dPCR (left panels) and number of copies/ul (right panel) were shown. The data points in the plot are color-coded according to the following call types:
FAM (blue), VIC (red), FAM+ VIC (green) and NOT AMPLIFIED (yellow)
Fig. 3 Absolute quantification of miRNA expression levels. a Bar
graphs show the number of copies/ul for mir-16-5p, mir-21-5p,
mir-126-3p, mir-486-5p and mir-660-5p in three different samples
(plasma, tissue and cells) (n = 3). Data are expressed mean ± standard
error of the mean. b mir-16-5p expression in different specimens:
healthy peripheral blood mononuclear cells (PBMC), normal lung
tissues and cell lines from breast cancer, fibroblast and osteosarcoma.
The experiments were done in duplicates
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Lung cancer cell lines
Human lung cancer cell lines, A549 and H1299, were
obtained from the American Type Culture Collection
(ATCC). LT73 cells were derived in our laboratory from
a primary lung tumor of a 68–year old Caucasian male
with lung adenocarcinoma [32].
PDX
Lung cancer patient’s derived xenografts (PDXs) were
developed by directly implanting fragments of the
patient’s living tumor in the flanks of immunocom-
promised mice [33].
Ethics statement
Tissue and plasma specimens were obtained according
to the Internal Review and the Ethics Boards of the
Istituto Nazionale Tumori of Milan (INT 2111). All pa-
tients provided informed consent.
MicroRNA profiling
Taqman assays
MiRNA expression was analyzed using Taqman MicroRNA
assays (Thermo Fisher Scientific) : mir-16-5p (ID:000391),
mir-21-5p (ID:000397), mir-126-3p (ID:002228), mir-486-
5p (ID:001278), mir-660-5p (ID:001515), cel-mir-39
(CUSTOM) and RNU48 (ID:001006).
Plasma
Total RNA was extracted from 200 μl plasma samples
using mirVana PARIS Kit (Thermo Fisher Scientific),
according to the protocol for biological fluids. Synthetic
C. elegans miRNA-39 (cel-miR-39) was used as spiked-in
control, adding to each plasma sample 5 μl from a 5
fmol/ μl stock tube (Qiagen). Samples were eluted in
50 μL of Elution Solution pre-heated at 95 °C to obtain
more concentrated total RNA.
RT reaction was performed on 3 μl of total RNA,
using the TaqMan MicroRNA Reverse Transcription Kit
Fig. 4 miRNAs expression levels in plasma samples. Bar graphs (left) show number of copies/μl of each miRNAs analyzed of three different
plasma samples and their respective ten-fold dilution. Representative dPCR plots of the miRNA analysis (right). The data points in the plot are
color-coded according to the following call types: FAM (blue), VIC (red), FAM + VIC (green) and NOT AMPLIFIED (yellow)
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and a Custom TaqMan RT Primer Pool (Thermo Fisher
Scientific), according to the manufacturer’s instruction.
Since we started from a small amount of total RNA, a
pre-amplification step of 12 cycle was required, thus
2.5 μL of each RT product were pre-amplified using a
Custom TaqMan PreAmp primer pool (Thermo Fisher
Scientific).
Tissues and cultured cells
PDX tissue samples were disrupted and homogenized
using 3 mm Tungsten Carbide Beads and the Mixer Mill
MM300 (Qiagen). For tissue samples and cultured cells,
total RNA was extracted using mirVana PARIS Kit
(Thermo Fisher Scientific) following manufacturer’s
instructions. Cel-miR-39 was used as spiked-in control,
by adding to each samples 5 μl from a 5 fmol/ μl stock
tube. Total RNA was quantified with the NanoDrop
2000 (Thermo Fisher Scientific).
Starting from 100 ng of total RNA, reverse transcription
was performed using the TaqMan microRNA Reverse
Transcription Kit and a TaqMan RT Primer Pool with the
miRNAs of interest according to the manufacturer’s
instruction (Thermo Fisher Scientific).
PCR on chip
We combined 2,25 μl of RT product (RT or PreAmp prod-
uct obtained in the previous step) with 3,75 μl nuclease-
free H2O, 7,50 μl QuantStudio™ 3D Digital PCR Master
Mix, 0,75 μl of TaqMan MicroRNA Assay-1 (20X) and
0,75 μl TaqMan MicroRNA Assay-2 20X (cel-mir-39-VIC).
To avoid pipetting errors, we prepared a stock solu-
tion and we included 10 % excess for volume loss from
Table 3 Absolute quantification of miRNA levels in plasma
Sample Assay cel-mir-39 CI- cel-mir-39 Target miRNA CI- miRNA Data points above
threshold (0.5)
PL 0 (1:5) 16–39 237,6 229,8 – 245,6 3748,5 3667,2 – 3831,7 18,686 of 19,678
PL 0 486-39 3438,1 3364,5 – 3513,4 4120,8 4020,8 – 4223,3 17,202 of 19,331
PL 0 660-39 2588,9 2539,8 – 2638,9 40,32 37,223 – 43,672 17,564 of 19,417
PL 0 (1:5) 1:10 16–39 24,3 21,8 – 27,0 387,8 376,6 – 399,4 15,745 of 16,444
PL0 1:10 486-39 184,9 177,6 – 192,5 175,2 168,2 – 182,6 16,184 of 17,874
PL 0 1:10 660-39 567,6 553,93 – 581,54 8,56 7,2– 10,2 17,082 of 19,260
PL 1 (1:5) 16–39 392,2 381,6 – 403,2 7856 7365,6 – 8379 17,875 of 19,224
PL1 486-39 2266,7 2224,4 – 2309,7 4295,9 4187,9 – 4406,6 17,220 of 18,865
PL 1 660-39 839,7 819,5 – 860,4 20,42 17,9 – 23,2 13,137 of 16,404
PL 1 (1:5) 1:10 16–39 46,1 42,8 – 49,8 1043,7 1022,8 – 1065 16,922 of 17,932
PL1 1:10 486-39 125,7 119,9 – 131,8 394,12 383,1 – 405,4 16,758 of 17,839
PL1 1:10 660-39 115,8 110,4 – 121,4 2,53 1,9 – 3,5 17,818 of 19,142
PL 2 (1:5) 16–39 286,8 276,8 – 297,2 6907,2 6535,1 – 7300,5 13,768 of 15,156
PL2 486-39 1141,1 1114,9 – 1168 567,2 551,1 – 583,7 12,279 of 19,292
PL2 660-39 1305,0 1279,7 – 1330,8 26,78 24,2 – 29,6 16,422 of 19,687
PL 2 (1:5) 1:10 16–39 43,7 40,4 – 47,2 877,4 859 – 896,2 16,864 of 19,038
PL2 1:10 486-39 188,3 181,0 – 195,9 112,8 107,3 – 118,6 16,513 of 19,004
PL2 1.10 660-39 123,1 117,4 – 129,0 1,9 1,4 – 2,8 17,112 of 18,704
Table 4 Pearson correlation in plasma samples between assays and samples
Real Time PCR (Ct) miR-16 mir-126 miR-486 mir-21 miR-660 Pearson correlation
PLASMA 1 17,86 19,87 20,83 24,63 28,57 −92 %
PLASMA 2 18,39 19,58 20,38 24,32 28,12 −89 %
PLASMA 3 18,59 18,88 21,35 24,66 28,76 −83 %
dPCR (copies/ul) miR-16 mir-126 miR-486 mir-21 miR-660
PLASMA 1 7590 4746,84 2882 755,79 37
PLASMA 2 6766 3261,78 3201 1855,87 41
PLASMA 3 6230 6840,79 643 913,46 27
Pearson correlation −99 % −76 % −93 % −98 % −87 %
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pipetting. This sample mix was added on each chip and
loaded on ProFlex™ 2x Flat PCR System with the fol-
lowing program (Table 1):
Absolute quantification was determined using Quant-
Studio 3D Digital PCR System (Thermo Fisher Scien-
tific) and analyzed with QuantStudio 3D AnalysisSuite
Cloud Software (Thermo Fisher Scientific).
Results and discussion
Chip quality control
The software assesses whether the data on a chip is
reliable based upon loading, signal, and noise character-
istics and displays quality indicators for each chip in a
project.
This quality control is based on the number of parti-
tions that exceed the selected quality threshold (fixed
automatically at 0.5) on the total number of wells filled
correctly. To get a precise quantification we settled a
threshold of 10.000 data points for quality control of
the chip (Additional file 1: Figure S1).
Use of spike-in (VIC fluorescence)
Several studies report on the use of synthetic RNA or
miRNA molecules as spike-in controls for mRNA/
miRNA expression data normalization [34–36].
In the proposed method, we decided to add in the mix
an exogenous spike-in miRNA (cel-mir-39 coniugated
with VIC fluorescence) as internal control for efficiency
of the whole reaction (from extraction to PCR) since the
fluorescence analysis using only FAM probes did not
allow a precise quantification of miRNAs.
To test the overall performance of the method in terms
of efficiency, precision, and sensitivity we generated a
standard curve using a serial dilution of cel-mir-39 mimic
Fig. 5 Absolute quantification of miRNAs in lung cancer cells. Bar graphs (left) show number of copies/μl of mir-16, mir-486 and mir-660 in
H1299 (upper), A549 (middle) and LT73 (lower) cell lines and their respective ten-fold dilution. Representative dPCR plots of the miRNA analysis
(right). The data points in the plot are color-coded according to the following call types: FAM (blue), VIC (red), FAM + VIC (green) and NOT
AMPLIFIED (yellow)
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(Qiagen). We generated a curve consisting in six points of
a five-fold serial dilution, starting from 5 fmol of cel-mir-
39 mimic. In this way the copy number of each single
miRNAs measured displayed a good linear response to in-
put mimic amount (Fig. 2). Furthermore, we calculated
the expected copies for each dilution of cel-mir-39 as de-
scribed by Hindson et al. [37] to show dPCR detection effi-
ciency assuming 100 % RT efficiency and an accurate
known concentration of the synthetic miRNA supplied by
the vendor (Table 2). We noted that absolute measure-
ments by dPCR corresponded to 74–115 % of the theoret-
ically input copies, indicating that absolute detection by
dPCR is remarkably efficient.
miRNA expression analysis
We decided to use our methodology for the quantification
of miRNAs levels in different type of samples (plasma,
tissue and cells) and its potential utility for cancer diagno-
sis of our 24 miRNAs composing the diagnostic signature
[15]. As shown in Fig. 3a, we analyzed the expression of
five miRNAs (mir-16-5p, mir-21-5p, mir-126-3p, mir-486-
5p and mir-660-5p) already demonstrated to have a role
in lung cancer development [32, 38–41]. This proposed
method could be useful for the quantification of miRNA
levels in various samples from normal or pathological con-
ditions. To demonstrate the potential use of this protocol,
we analyzed the expression of mir-16-5p, an ubiquitous
miRNA, in different specimens as healthy peripheral
blood mononuclear cells (PBMC), normal lung tissue and
cell lines of breast cancer, fibroblast and osteosarcoma
(Fig. 3b).
Plasma analysis
To evaluate the sensitivity and the precision of our
digital PCR methods, we select three of the selected
miRNAs showing different levels of expression (i.e. mir-
16-5p mir-486-5p and mir-660-5p) and analyzed their
expression in plasma samples. On the basis of the
expected circulating miR-16-5p levels, we performed a
five-fold dilution of the samples to have high efficiency
of quantification compared to the undiluted sample
(data not shown for undiluted sample). For the other
two miRNAs, mir-486-5p and mir-660-5p, no dilution
was required (Fig. 4 and Table 3). To compare results
obtained with qPCR, we tried to correlate raw Ct data
for these five circulating miRNA obtained with custom
microfluidic cards [20] and the number of copies ob-
tained with dPCR (Table 4) assuming 100 % primers effi-
ciency as described by the vendor. As reported in
Table 4, we observed a good correlation intra-run assay
and between samples for circulating miRNAs analyzed.
To demonstrate the specificity of the absolute quantifi-
cation, we performed a ten-fold dilution for each samples
and we confirmed that there was a linearity for each miR-
NAs between the two samples (fold-dilution average
between samples: mir-16-5p: 8,81 ± 0,675, mir-486-5p:
7,67 ± 2,41, mir-660-5p: 9,96 ± 1,76).
Table 5 Number of miRNAs copies in lung cancer cell lines
Sample Assay cel-mir-39 CI- cel-mir-39 Target miRNA CI- miRNA Data points above
threshold (0.5)
H1299 16–39 981,8 962,5 – 1001,5 5025,6 4880,6 – 5175 18,079 of 18,671
H1299 486-39 940,9 921,7 – 960,6 17,1 15,1 – 19,4 17,084 of 19,738
H1299 660-39 1.275,7 1252 – 1299,8 112,7 107,5 – 118,2 18,148 of 19,385
H1299 1:10 16–39 302,9 293,4 – 312,8 439,3 427,4 – 451,5 16,281 of 18,954
H1299 1:10 486-39 345,8 335,8 – 356,1 1,8 1,2 – 2,6 17,328 of 18,723
H1299 1:10 660-39 334,3 324,4 – 344,5 9,2 7,7 – 10,9 16,976 of 18,096
A549 16–39 808,9 790,1 – 828,3 2130,9 2087,6 – 2175,1 14,270 of 19,057
A549 486-39 1309,6 1285,3 – 1334,3 19,9 17,8 – 22,3 18,008 of 19,310
A549 660-39 1403,2 1372,5 – 1434,6 69 64,0 – 74,0 12,610 of 17,988
A549 1:10 16–39 486,6 473,6 – 499,9 483,4 470,5 – 496,7 15,486 of 16,723
A549 1:10 486-39 401,3 379,9 – 423,8 1,57 0,7 – 3,5 17,285 of 18,655
A549 1:10 660-39 367,4 355,9 – 379,5 5,36 4,1 – 6,8 13,841 of 17,322
LT73 16–39 655,2 640,7 – 670,1 3266,7 3200,2 – 3334,5 18,070 of 19,251
LT73 486-39 921,1 902,2 – 940,4 16,5 14,6 – 18,8 17,170 of 18,120
LT73 660-39 574,0 558,7 – 589,8 4,0 3,0 – 5,3 13,606 of 19,582
LT73 1:10 16–39 90,4 85,5 – 95,5 409,9 398,6 – 421,5 16,673 of 18,990
LT73 1:10 486-39 66,8 62,7 – 71,1 1,3 0,9 – 2,1 17,359 of 18,326
LT73 1:10 660-39 60,8 57,0 – 64,8 0,3 0,1 – 0,8 18,164 of 19,404
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The number of copies per μl between samples was
normalized based on the mean of cel-mir-39 expression
for each chip and multiplied by the number of dilution
folds in the plasma.
We replicated miRNAs expression analysis on three
different plasma samples and we obtained similar data of
expression for each miRNAs (Fig. 4 and Table 3). Negative
and non-template controls for each miRNA were run on
chip and did not show any positive results.
Cell analysis
To demonstrate the potential use of QuantStudio 3D
digital PCR for cellular miRNAs expression analysis, we
analyzed the levels of these miRNAs in three different
lung cancer lines. As already described, mir-16-5p is one
of the most abundant miRNA in lung cancer cells,
whereas mir-660 and mir-486-5p expression is very low.
Starting from 100 ng of total RNA, we quantified the
miRNA expression levels using undiluted or ten-fold
diluted samples (Fig. 5 and Table 5). As shown in the
graphs the sensitivity of the method was confirmed also
for miRNA cellular expression (fold-dilution average be-
tween samples: mir-16-5p: 10,45 ± 3,87, mir-486-5p:
12,45 ± 2,95, mir-660-5p: 10,99 ± 3,69). Moreover, we
performed RNU48 analysis cell samples and we observed
that the number of copies for RNU48 was similar for all
the samples starting from the same amount of input
RNA (data not shown). Negative and non-template con-
trols for each miRNA were run on chip and did not
show any positive results
PDX analysis
Our method could be applied for the analysis of miR-
NAs expression in tissues and to demonstrate this
potential use we performed the same analysis described
above. We extracted RNA and measured miRNAs levels
from three different samples of our patients derived
xenografts. As described in Fig. 6 and Table 6, mir-16
Fig. 6 Number of miRNAs copies per μl in lung PDX tissues. Bar graphs (left) show the expression levels of the miRNAs analyzed in three
different samples of PDX and their respective ten-fold dilution. Representative dPCR plots of the miRNA analysis (right). The data points in the plot
are color-coded according to the following call types: FAM (blue), VIC (red), FAM + VIC (green) and NOT AMPLIFIED (yellow)
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was the most expressed miRNAs in tissues whereas mir-
486 and mir-660 had similar expression levels. Ten fold
dilution of the samples confirmed the sensitivity of the
analysis in tissues (fold-dilution average between sam-
ples: mir-16-5p: 9,92 ± 2,18, mir-486-5p: 10,39 ± 1,32,
mir-660:-5p 11,03 ± 1,92). As described above, we per-
formed RNU48 analysis on all tissues and we observed
that the number of copies for RNU48 was similar for all
the samples starting from the same amount of input
RNA (data not shown). Negative and non-template con-
trols for each miRNA were run on chip and did not
show any positive results.
Precision of the methodology
To determine repeatability of the methods we performed
mir-16-5p analysis on 5 different samples in duplicates
and measured the coefficient of variation [37] in the same
PCR run. The same samples were also analyzed in two dif-
ferent PCR runs to determine the overall precision of the
methodology. As shown in Table 7, digital PCR results
displayed low variation both intra and inter-run replicates
(% CV within-run: 4 %; overall precision: 4 %) (Table 7).
Conclusion
In this work, we developed for the first time a new
method for the detection of miRNAs in different type of
biological specimen as plasma, cell lysates or tissue. This
method could be particularly useful for quantification of
miRNAs in those biological samples, such as plasma/
serum or exosomes, where lack of consensus for the
normalization strategy prevents clinical applications.
Digital PCR has a great potential but several tips need
to be followed: first a rough estimate of the concentra-
tion of your target of interest has to be previously done
in order to make appropriate dilutions. Otherwise, it is
possible that too many partition will get multiple copies
preventing an accurate calculation of the copy number
of your miRNA. Furthermore, non-template controls
and a RT negative control must be set up for each
miRNA when using a “primers pool methods” for retro-
transcription.
A chip-based digital PCR approach has the advantage
to require less pipetting steps and to reduce PCR
contamination. In comparison, the droplet digital PCR
requires multiple pipette transfers that could potentially
increase the risk of contamination. Furthermore, Quant-
Studio 3D chips have 20.000 fixed reaction wells whereas
Table 6 miRNAs levels in PDXs tissues
Sample Assay cel-mir-39 CI- cel-mir-39 Target miRNA CI- miRNA Data points above
threshold (0.5)
PDX 1 16–39 430,6 418 – 443,5 968,4 946,9 – 990,4 14,289 of 18,775
PDX1 486-39 682,8 666,8 – 699,1 45,2 41,8 – 48,9 15,843 of 18,068
PDX 1 660-39 521,2 507,9 – 534,9 18,8 16,7 – 21,2 16,106 of 18,346
PDX 1 1:10 16–39 122,4 105,8 – 141,7 162,29 155,7 – 169,2 18,068 of 19,395
PDX1 1:10 486-39 58,0 54,3 – 62,1 2,93 2,2 – 3,9 17,381 of 19,135
PDX1 1:10 660-39 52,7 47,5 – 58,4 1,72 0,9 – 3,0 17,868 of 18,826
PDX 2 16–39 601,9 586,6 – 617,7 937,7 916,8 – 958,9 14,472 of 16,749
PDX 2 486-39 532,9 520,1 – 546,1 23,8 21,5 – 26,4 17,831 of 19,264
PDX 2 660-39 441,6 426,6 – 457,2 23,2 20,2 – 26,5 10,233 of 15,163
PDX 2 1:10 16–39 59,7 55,9 – 63,8 134,7 128,8 – 140,9 17,341 of 19,135
PDX 2 1:10 486-39 57,5 53,2 – 62,2 1,5 0,9 – 2,4 13,040 of 18,311
PDX 2 1:10 660-39 62,3 58,3 – 66,4 2,8 2,1 – 3,8 17,358 of 19,226
PDX3 16–39 83,5 78,9 – 88,4 798,1 781,0 – 815,5 17,174 of 19,355
PDX3 486-39 104,7 98,6 – 111,2 9,9 8,2 – 12,0 12,183 of 18,035
PDX3 660-39 86,1 81,5 – 91,1 9,0 7,6 – 10,7 17,004 of 18,146
PDX3 1:10 16–39 12,9 11,2 – 14,8 90,5 85,6 – 95,5 17,089 of 18,817
PDX3 1:10 486-39 7,3 6,7– 8,7 0,5 0,3 – 1,0 17,966 of 19,844
PDX3 1:10 660-39 7,7 6,4 – 9,2 0,5 0,3– 1,1 17,509 of 19,282
Table 7 Coefficient of variation between dPCR replicates
CV across intra-run replicates CV across inter-run replicates
Sample 1 0,004 0,05
Sample 2 0,033 0,02
Sample 3 0,009 0,02
Sample 4 0,008 0,07
Sample 5 0,142 0,04
Average 0,039 0,040
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droplet PCR rely upon the generation of droplets, a step
that could be extremely variable. Overall, our proposed
method for miRNA quantification using a chip-dPCR
were comparable in terms of accuracy and precision to
the study reported by Miotto et al. using droplet digital
PCR. (% CV within-run: chip 4 % droplet 5.1; overall
precision: chip 4 % and droplet 13 %) [42].
Obviously, this approach has some limitations, for
example, the ability to perform only one sample per
chip, although it is possible to load in the thermocycler
up to 24 chips. Moreover, using this approach tests in
multiplex fluorescence can be carried out but only with
two probes per chip. To date, dPCR could be potential
useful for clinical diagnostic purpose only for small scale
samples but we believe that, during the next years, the
improvement of the methodology could permit multi-
plexing analysis. At the time, the instrument is not able
to perform an accurate analysis when there is only one
fluorescence, VIC or FAM, because it is set to choose a
threshold for both fluorescence. In our methods, to solve
this technical problem, we decided to put a reference
control, an exogenous spike-in with VIC probe, which
allows an accurate miRNA copy number quantification
and also to have control of the whole process. A new
version of the analysis software, now released, permit
manual modifications of the fluorescence parameters
such as threshold or scale of the axis. Nonetheless, the
instruments take up to three minutes for the reading
and the analysis of one chips and thus can be potentially
used in a clinical diagnostic setting.
Additional file
Additional file 1: Figure S1. Review quality of dPCR chip.
Representative images shown chips with good quality as data points
above threshold or by calls (upper) and chips below the sufficient quality
for miRNAs detection (lower). The data points in the plot are color-coded
according to the following call types: FAM (blue), VIC (red), FAM + VIC
(green) and NOT AMPLIFIED (yellow). (BMP 1250 kb)
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